-- Earnings Flash (PALI) PALISADEBIO Posts Q1 Loss $-0.26
9:00AM ET 5/13/2022 MT Newswires...
Quotes Snapshot > PALI
Palisade Bio Inc PALI:NASDAQ
Last Price$0.45NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/24/22
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$0.45 (13)
Ask (Size)$0.50 (1)
Day Low / HighN/A - N/A
Volume111.4 K
Read more news Recent News
Palisade Bio to Launch $2 Million Registered Direct Offering; Shares Tumble Early
9:39AM ET 5/06/2022 MT NewswiresPalisade Bio (PALI) said Friday that it will launch a registered direct offering of 3,646,690 of its shares at $0.55 each for gross proceeds of about $2...
Palisade Bio Gets FDA Nod to Phase 3 Study to Accelerate Bowel Function After Surgery; Shares Surge Pre-Bell
8:57AM ET 3/22/2022 MT NewswiresPalisade Bio (PALI) said Tuesday it received a letter from the US Food and Drug Administration that paves the way for a phase 3 clinical trial to evaluate...
Palisade Bio Files $100 Million Mixed Shelf
3:30AM ET 3/21/2022 MT NewswiresPalisade Bio (PALI) on Friday filed a shelf registration statement for the potential sale of up to $100 million of its securities from time to time. The...
View all Commentary and Analysis
Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund
11:11AM ET 5/08/2022 Seeking AlphaPalisade Bio: Guarding Intestinal Integrity
4:55AM ET 11/07/2021 Seeking AlphaCompany Profile
Business DescriptionPalisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA. View company web site for more details
| Address | 5800 Armada Drive Carlsbad, California 92008 |
| Phone | +1.858.704.4900 |
| Number of Employees | 6 |
| Recent SEC Filing | 06/23/2022 EFFECT |
| Chief Executive Officer & Director | Thomas M. Hallam |
| Senior VP-Operations & Strategic Development | Robert McRae |
| Chief Financial Officer | J. D. Finley |
| Finance Director & Controller | Ryker Willie |
Company Highlights
| Price Open | $0.49 |
| Previous Close | $0.45 |
| 52 Week Range | $0.40 - 4.57 |
| Market Capitalization | $9.8 M |
| Shares Outstanding | 21.9 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/23/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$4.74 |
| Beta vs. S&P 500 | N/A |
| Revenue | $260.0 K |
| Net Profit Margin | N/A |
| Return on Equity | -1,794.66% |
Analyst Ratings as of 02/01/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |